NCT04865978View on ClinicalTrials.gov

Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 14, 2021

Primary Completion Date

October 5, 2023

Study Completion Date

November 7, 2023

Conditions
Heart Failure
Interventions
DRUG

Apixaban

Patients randomized to apixaban will be started on a dose of 5 mg BID.

DRUG

Warfarin

Patients randomized to warfarin will be started on a dose per institutional protocol and titrated to an INR goal of 2.0 - 2.5.

DEVICE

LVAD implant

Subjects will undergo HeartMate 3 LVAD implant prior to randomization

Trial Locations (1)

22042

Inova Fairfax Medical Campus, Falls Church

Sponsors

Collaborators (1)

Abbott Medical Devices
All Listed Sponsors
collaborator

Abbott Medical Devices

INDUSTRY

lead

Palak Shah

OTHER

NCT04865978 - Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices | Biotech Hunter | Biotech Hunter